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AbSTrACT:
Objectives The assessment of spondyloarthritis 
international society (asas) aimed to develop a set of 
quality standards (Qs) to help improve the quality of 
healthcare provided to adult patients affected by axial 
spondyloarthritis (axspa) worldwide.
Methods an asas task force developed a set of 
Qs using a stepwise approach. First, key areas for 
quality improvement were identified, discussed, rated 
and agreed on. Thereafter, areas were prioritised and 
statements for the most important key areas were 
phrased on consensus. appropriate quality measures 
were defined to allow quantification of the Qs at the 
community level.
results The asas task force, consisting of 20 
rheumatologists, two physiotherapists and two patients, 
selected and proposed 34 potential key areas for quality 
improvement which were then commented by 140 asas 
members and patients. Within that process three new key 
areas came up, which led to a re- evaluation of all 37 key 
areas by 120 asas members and patients. Five key areas 
were identified as most important to determine quality 
of care: referral including rapid access, rheumatology 
assessment, treatment, education/self- management 
and comorbidities. Finally, nine Qs were agreed on and 
endorsed by the whole asas membership.
Conclusions asas successfully developed the first set 
of Qs to help improving healthcare for adult patients 
with axspa. even though it may currently not be realistic 
to achieve the Qs in all healthcare systems, they provide 
high- quality of care framework for patients with axspa 
that should be aimed for.
InTrOduCTIOn
Axial spondyloarthritis (axSpA) is a chronic inflam-
matory disease of the axial skeleton with inflam-
matory back pain as the major symptom, and 
spinal/sacroiliac joint inflammation and new bone 
formation as the most pathognomonic features.1 
There is wide variation in the delivery and quality 
of healthcare for patients with axSpA. The mission 
of the Assessment of SpondyloArthritis Interna-
tional Society (ASAS) as an international group of 
experts in the field of spondyloarthritis (SpA) is to 
support and promote the study of axial and periph-
eral SpA, to increase awareness and early diagnosis 
of the disease, to develop and validate assessment 
tools, and to evaluate treatment modalities in 
order to promote clinical research with the ulti-
mate goal to improve outcome of the disease (ASAS 
website: www. asas- group. org). Several unmet needs 
such as delayed diagnosis and restricted access to 
treatment have been described in many countries 
Key messages
What is already known about this subject?
 ► Wide variation in the delivery and quality 
of healthcare for patients with axial 
spondyloarthritis (axSpA) exists.
 ► Provision of measurable constructs can help to 
identify key gaps in the current provision care at 
the community level
 ► Quality assessment tools have been published 
for several rheumatological conditions; none 
relate specifically to patients with axSpA.
What does this study add?
 ► Assessment of SpondyloArthritis International 
Society (ASAS) developed the first set of quality 
standards to help improving health care for 
adult patients with axSpA.
 ► Quality standards have been formulated for 
key area of referral, rheumatology assessment, 
treatment, education/self- management and 
comorbidities.
How might this impact on clinical practice or 
future developments?
 ► ASAS quality standards provide high- quality 
of care framework for patients with axSpA 
intending to help organisations improve quality 
of care and to monitor service improvements.
 ► ASAS quality standards are achievable in daily 
care in an optimised situation and intend to 
minimise variation in quality of care.
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worldwide.2 3 These and other gaps in current care provision 
prompted ASAS in 2016 to start developing a set of quality stan-
dards (ASAS- QS) to help optimise access, treatment and patient 
outcomes in axSpA. Although the diagnostic delay has somewhat 
decreased in recent years, this is still significant when compared 
with rheumatoid or psoriatic arthritis.4 5 Furthermore, the avail-
ability and quality of health and care provision across rheuma-
tological diseases varies worldwide due to different economic 
and political realities and healthcare systems.3 Thus, assessing 
the quality of care provided to patients with axSpA is important 
not only to patients and physicians, but also to providers and 
purchasers of healthcare.6
There is no agreed methodology to quantify quality of care. 
According to the US Institute of Medicine quality measures assess 
“the degree to which health services for individuals and popu-
lations increase the likelihood of desired health outcomes and 
are consistent with current professional knowledge”.7 Different 
validated measurement sets such as quality indicators, perfor-
mance measures or quality standards (QS) have been suggested 
to establish measurable constructs.8 9 To date, quality assessment 
tools have been published for several rheumatological conditions 
like inflammatory arthritis, rheumatoid arthritis and gout,10–12 
but none of these relate specifically to patients with axSpA.
The UK based National Institute of Clinical Excellence (NICE) 
has a long trajectory of developing QS defined as a set of state-
ments to help improve quality of health and care services and 
very recently published a quality assessment tool for patients 
with axSpA.13 The different measurement sets relate to measur-
able aspects of healthcare, and in contrast to guidelines or 
recommendations, the measurement sets do not reflect all stages 
and levels of disease status.
ASAS decided to choose QS as quality assessment tool, 
based on the methodology used by NICE. NICE specifies QS 
should be developed to cover areas where there is variation 
of care and identify resources and processes which need to be 
optimised in order to achieve quality improvement.14 QS offer 
the opportunity to define measurable constructs which can be 
operationalised in structural or process related characteristics of 
healthcare as defined by Donabedian.15 Donabedian’s classical 
theoretical framework for measuring healthcare quality includes 
three related categories of which the first two, that is, structures 
(innate characteristics of providers and the system), and processes 
(what healthcare providers do in delivering care), influence the 
third category: outcomes (what happens to patients, particularly 
with respect to their health).
Improvement in quality of care should focus on those areas 
in which there is evidence of variation in the delivery of care. 
Those key areas for quality improvement should identify key 
requirements for high- quality care or service provision that are 
expected to contribute to improving the experience of care or 
services as well as their safety and effectiveness. However, topics 
have to be balanced between ideal settings and actual clinical 
practice settings and QS should therefore describe enhanced 
practice, which is aspirational but achievable in daily care.
Thus, our objective was to develop international QS to 
improve the quality of care for adult patients with axSpA by 
identification of key gaps in the current provision care at the 
community level.
MeTHOd
First, in order to operate its QS programme, ASAS nominated two 
groups: a Steering Committee (JB, UK, RL, MR, DvdH, MW) 
and a QS group tasked with the development of an ASAS- QS set. 
This QS group was formed by ASAS members proposed by the 
ASAS Executive Committee, based on their clinical and research 
experience in outcome and management of SpA. The ASAS- QS 
group decided to (1) invite additional patients and healthcare 
professionals in order to meet priorities and to guarantee repre-
sentativeness of the group and (2) to utilise the pre- existing ASAS 
recommendations for early referral for patients with a suspicion 
of axSpA and ASAS recommendations for the management of 
axSpA as scientific key source guidance.16 17 All ASAS members 
are actively involved in scientific projects and ASAS members are 
referred here as ‘ASAS community’.
The ASAS- QS group used a stepwise approach to develop 
a disease- specific set of QS for adult patients with axSpA 
(figure 1). ASAS decided to base any subsequent methodological 
approach on NICE quality standard process guide excluding any 
reference or involvement to payers of the health system as this 
differs widely across countries.14 In order to meet stakeholder 
priorities, ASAS members were asked twice to identify key areas 
for quality improvement in an attempt to understand all relevant 
medical needs and gaps at a national level.
Each quality standard consists of two components: a quality 
statement and a quality measure. A quality standard set addresses 
key areas for quality of care improvement by providing specific, 
clear, concise, and measurable statements that are derived from 
evidence- based guidance. Each quality statement is accompanied 
by a quality measure which is meant to quantify the quality of 
care or service provision specified in the statement by providing 
a numerator and a denominator. Further, each quality standard 
is accompanied by a rationale providing the scientific evidence 
and the guidance and definitions of the terms used for each 
specific quality statement.
The following steps were undertaken to develop the ASAS- QS 
for adult patients with axSpA:
1. Provisional list of key areas for quality improvement: ASAS- 
QS group members convened at a face- to- face 1- day meeting 
to set up the remit of the work in Berlin in January 2016. 
After an extensive open discussion, it was decided to use a 
stepwise approach by starting with the identification of pos-
sible key areas for quality improvement. This should be areas 
in which variation in care exists but which can be improved 
and which are measurable and achievable. Key areas for qual-
ity improvement were grouped into the categories structure, 
process and outcomes to help guiding the subsequent steps.
2. Evaluation of the provisional list of key areas for quality im-
provement: During summer 2016, ASAS members and pa-
tient representatives were invited via a web- based survey to 
comment on this provisional list and to identify additional 
key areas for quality improvement not mentioned before in 
the provisional list. Patient representatives were invited via 
the national patient organisation. Participants were asked to 
agree or disagree to each single QS item. ASAS- QS group 
agreed that a key area for quality improvement would be 
considered as important when ≥25% of the participants—
independent of being patient or professional—agreed to the 
key areas for quality improvement. Participants received 
background information on the definition and process de-
velopment of QS prior to starting the survey to reduce prob-
ability of misinterpretation or misunderstanding. ASAS- QS 
group and two patient representatives met to discuss the 
findings of the web- based survey in a face- to- face meeting 
(September 2016).
3. Prioritisation of key areas for quality improvement: All par-
ticipants who completed step 2 were then invited to actively 
contribute to the development process and to comment on 
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Figure 1 Summary of the nine Assessment of SpondyloArthritis International Society quality statements. SpA, spondyloarthritis.
the complete list of key areas for quality improvement via a 
web- based survey. They received background information on 
QS prior to starting the survey. Participants were then asked 
to prioritise key areas for quality improvement by indicating 
level of importance on a numerical rating scale (NRS) 0 (not 
important at all) to 10 (very important). A threshold of 75% 
of participants reaching ≥8 on NRS—independent of being 
patient or professional—was considered as reflecting an im-
portant key area for quality improvement. As there was no 
guidance for a cut- off in the literature, the steering group 
decided to use a strict cut- off for agreement to ensure a select 
decisions made based on wide agreement.
4. Identification of final key areas for quality improvement: 
ASAS- QS members discussed in a 1- day meeting (January 
2017) the further methodology. As part of this process, the 
most important key areas for quality improvement from step 
3 were regrouped into domains for which quality statements 
and measures should be developed. The ASAS- QS group was 
then asked to propose phrasing of important QS.
5. Phrasing of QS: ASAS- QS members drafted a statement, ra-
tionale and measure for selected key areas in a 1- day meeting 
(January 2018). If necessary, aspects were phrased in more 
than one statement. Phrasing of the QS was influenced by 
proposals of the ASAS community.
6. Voting on ASAS- QS: ASAS- QS group presented the ASAS- QS 
set to the ASAS community in January 2018 and discussed 
the content, applicability and implementation of the final 
ASAS- QS set. Subsequent to the meeting the ASAS members 
were again asked to give the level of agreement on an NRS 
0 (I do not agree at all) to 10 (I fully agree) in a web- based 
survey. A threshold of 75% of participants reaching ≥7 on 
NRS was needed to be agreed by the ASAS community.
a. Re- evaluation on QS 1 and 2: QS 1 and 2 provoked dis-
agreement and required further discussions. Therefore, 
the ASAS- QS group provided background information 
and education sessions on meaning and intention of QS 
and discussed rephrasing of final ASAS- QS set. ASAS 
members were invited in November 2018 to comment 
on QS 1 and 2 in a web- based survey by answering the 
following questions: “I agree to the phrasing of QS 1 (2, 
respectively) and do not wish a change of this quality 
statement”. Participants who affirmed the question were 
asked to rate the level of agreement on an NRS 0 (I do 
not agree at all) to 10 (I fully agree). Participants who 
denied the question were asked to share thoughts about 
QS 1 (2, respectively) and to specify disagreement.
7. Endorsement by the ASAS membership: ‘Pro’ and ‘con’ ar-
guments to QS 1 and 2 were exchanged during the annual 
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Clinical 
symptoms 
Diagnosis/ 
Differential -
diagnosis 
Treatment 
Management 
Non-rheumatology Care 
OS 1 Referral: People with suspicion of axial SpA are referred to a 
rheumatologist for diagnostic assessment within 3 working days. 
Rheumatoloqy care 
OS 2: Time to Sgecialist OS 3: Assessment 
People with suspicion of axial People with suspected axial SpA 
SpA are assessed by a have their diagnostic work-up 
rheumatologist within 3 weeks completed within 2 months. 
after referral. 
OS 4: Monitoring OS 5: Disease OS 6: Non 
Disease Activity: Control gharmacological 
Treatment 
Disease activity of In people with axial 
people with axial SpA SpA and active People with axial 
is monitored under the disease despite SpA are informed 
supervision of a conventional about the benefits 
rheumatologist with therapy , treatment of regular 
validated composite escalation with exercise. 
scores at least twice a biologics is 
year. discussed. 
OS 7: Education and OS 8: Ragid Access OS 9: Annual 
Self-management Review 
Patients with axial 
People with axial SpA SpA and disease People with axial 
are offered education flare or possibly SpA have a 
on the disease drug-related side comprehensive 
including seif- effects receive annual review by 
management within advice within 2 the 
two months of working days of rheumatologist. 
diagnosis. contacting the 
rheumatologist. 
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ASAS meeting in January 2019 in Amsterdam. After exten-
sive discussion, a simple vote for agreement/disagreement of 
QS 1 and 2 was taken from ASAS members.
reSulTS
The ASAS- QS group consists of 20 rheumatologists, two physio-
therapists and two patient research partners.
1. Provisional list with key areas for quality improvement: The 
ASAS- QS group developed in January 2016 (Berlin) a list 
with 34 potential key areas for quality improvement (online 
supplementary file 1). Key areas were grouped into the cate-
gories structure (n=7), process (n=23) and outcome (n=4).
2. Evaluation of the provisional list of key areas for quality im-
provement: 140 participants (86 ASAS members and 42 ax-
SpA patients from 10 countries (Belgium, France, Germany, 
Israel, the Netherlands, Portugal, Spain, Turkey, UK, USA), 
12 participants did not provide demographics, see online 
supplementary file 2) evaluated the provisional list of key 
areas for quality improvement in summer 2016 via a web- 
based survey. Five new key areas for quality improvement 
were proposed (one item for the category structure (structur-
al support for physiotherapist- led exercise), two items for the 
category process (extra- articular manifestation and assess-
ment of current treatment), and two items for the category 
outcome (percentage of patients who improved in mobility 
as measured by physiotherapists tests and percentage of hos-
pital admissions for complicated disease)). The rate of mis-
understanding was low, in most cases <5%, except for co-
morbidities (8.6%), morphometric assessment (26.4%), cor-
rective osteotomy (15.0%), and total arthroplasty (13.6%). 
All key areas for quality improvement initially proposed by 
the group reached the threshold of 25% agreement (mean 
agreement to the categories structure 83.8%, process 79.5% 
and outcome 56.8%. Agreement with each single key area is 
shown in online supplementary file 1. The results of the sur-
vey were presented to the ASAS- QS group and two patient 
representatives at a meeting in Ghent in September 2016 
where future steps regarding the prioritisation of key areas 
for quality improvement and content validity of possible QS 
were extensively discussed.
3. Prioritisation of key areas for quality improvement: In au-
tumn 2016, 120 participants (86 physicians, 29 patients, 
five participants did not provide demographics, see online 
supplementary file 2) prioritised in a web- based survey 39 
key areas for quality improvement, across three categories 
structure, process and outcome (see online supplementary 
file 2). Key areas were prioritised between 4.5 and 8.6 (see 
online supplementary file 1). Five key areas were rated as 
most important: timely diagnosis, documentation of diagno-
sis, patient information, assessment of disease activity, and 
assessment of infection risks when starting biologicals.
4. Identification of final key areas for quality improvement: 
ASAS- QS group met in January 2017 in Leeds and decid-
ed to omit the strict segmentation in structure, process and 
outcome and rather phrase QS which may cover more than 
one of the categories structure, process and outcome. ASAS 
QS grouped selected key areas into superordinate domains: 
referral including rapid access, rheumatology assessment, 
treatment, education including self- management and comor-
bidities. The ASAS community provided detailed proposals 
about phrasing of most important domains.
5. Phrasing of QS: the ASAS- QS group drafted nine QS for ax-
SpA encompassing a statement and a rationale, in January 
2018 in Lisbon (tables 1–3). Since the identified key areas 
represent domains which can be applied in a wide context, 
it was necessary to think about their application in differ-
ent clinical settings leading to more than one QS for one 
key area. Phrasing of QS was influenced by proposals of the 
ASAS community from step 4. Statements were provided 
for aspects of referral and rapid access (n=4), rheumatolo-
gy assessment (n=1), treatment (n=2), education (n=1) and 
comorbidities (n=1). Whenever timelines were mentioned, 
timelines were developed by consensus within the ASAS- QS 
group. The timelines were not data driven and represent the 
‘aspirational but achievable’ aspect of the ASAS- QS which 
are presumably related to different national perception.
6. Voting on ASAS- QS: the proposed ASAS- QS were presented 
to the membership at the annual ASAS meeting in Lisbon in 
January 2018. At this meeting, the ASAS community inten-
sively discussed the content, applicability and implementa-
tion of the final ASAS- QS set. One item in particular, the 
timeframes given in QS 1 and 2 was a matter of debate. Sub-
sequent, voting in August 2018 among 115 ASAS members 
showed (too) low agreement for QS 1 and 2, whereas agree-
ment was substantially higher for QS 3–9 (tables 1–3).
a. Re- evaluation of the final set of ASAS- QS: During August 
and November 2018, the ASAS- QS group provided back-
ground information and education sessions on meaning 
and intention of QS in general to ASAS community. In 
November 2018, 73 ASAS members provided feedback to 
QS 1 and 2. Disagreement to QS 1 was raised by 24 mem-
bers of the ASAS community (32.9%) whereas agreement 
to QS 1 was stated by 49 members (67.1%). Agreement 
was documented by a high value of mean level of agree-
ment (NRS 8.1 (1.9), ≥7:92.1%). Disagreement to QS 
2 was raised by 18 members (25%) whereas agreement 
to QS 2 was stated by 54 members (75%) (one missing 
response). Agreement was documented by a high value of 
mean level of agreement (NRS 7.9 (1.9), ≥7:87.1%). Ar-
guments for disagreement of QS 1 were based on defined 
timeframe of three working days (‘unrealistic setting’), 
exertion of rheumatologists on decisions made in general 
practitioner (GP) area, and unclear definition of the term 
‘suspicion of axSpA’. Arguments for disagreement of QS 
2 were based on the defined timeframe of 3 weeks and 
lack of possibility of rheumatologist to intervene with a 
centralised appointment system.
7. Endorsement: QS 1 and 2 were discussed at the ASAS annual 
meeting in Amsterdam in January 2019. After extensive dis-
cussion, it was decided not to change the initially proposed 
phrasing of QS 1 and 2 and 98 ASAS members voted to re-
tain QS 1 and 2 unchanged (QS 1: 77 approval, 10 decline, 
0 abstention; QS 2: 72 approval, 11 decline, four abstention) 
(table 1).
Quality measures were drafted after the wording of the 
quality statements was agreed by the ASAS- QS group. All quality 
measures related to processes are expressed as a numerator and 
a denominator to define a proportion (numerator/denominator) 
(tables 1–3).
dISCuSSIOn
ASAS successfully developed the first QS set for the improve-
ment of the quality of health and care services provided to 
adults with axSpA. These QS include a clear description of high 
priority areas for quality improvement and monitoring. Signifi-
cant differences in the availability and quality of healthcare may 
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Table 1 Quality standards (QS) for axial spondyloarthritis, clinical symptoms and diagnosis
no domain Statement rationale
Quality measure, 
category structure
Quality 
measure, 
category 
process, 
numerator
Quality measure, 
category 
process, 
denominator
level of 
agreement, 
nrS 0–10
Agreement 
(nrS ≥7 by 
75% of ASAS 
members)
QS1 Referral Patients with 
suspicion of 
axSpA are 
referred to a 
rheumatologist 
for diagnostic 
assessment 
within three 
working days
When axSpA is suspected, ASAS 
recommendations for the early 
referral of patients with a clinical 
suspicion of axSpA provide criteria 
for deciding whether the patient 
should be referred to rheumatology 
for special diagnostic assessment. 
AxSpA is often missed in non- 
specialist settings, resulting in 
substantial delays in diagnosis and 
treatment. No single test has been 
shown to have sufficient sensitivity 
or specificity to diagnose axSpA. 
Timeframe of three working days is 
expert- driven intending to trigger 
immediate referrals.
Evidence of local 
arrangements 
(including local 
arrangements to 
raise awareness of 
signs and symptoms 
of axSpA) and 
written protocols to 
ensure that patients 
with suspicion for 
axSpA are referred to 
rheumatology within 
three working days.
The number of 
patients with 
a suspicion 
of axSpA that 
is referred to 
rheumatology 
within three 
working days.
The number of 
patients with 
a suspicion of 
axSpA.
6.0±3.1
second vote: 
88.5%.
47.8
QS2 Time to 
specialist
Patients with 
suspicion of 
axSpA are 
assessed by a 
rheumatologist 
within 3 weeks 
after referral
Rapid referral of patients with 
suspicion of axSpA is important to 
avoid delay in diagnosis and increase 
the likelihood of early treatment 
initiation. A rheumatologist (which 
implies the rheumatology team 
including physicians, nurses, and 
other health professionals) is able 
to identify axial and peripheral 
manifestations as well as extra- 
articular manifestations and 
comorbidities. Given the potentially 
detrimental effects of delayed 
diagnosis, patients with these 
symptoms and signs are in need of 
a first appointment within 3 weeks. 
Timeframe is expert- driven intending 
to trigger timely appointments. 
Timeframe of 3 weeks refers to 
a first appointment. Additional 
examinations required for decision- 
making process can follow after the 
first appointment.
Evidence of local 
arrangements 
including sufficient 
number of 
rheumatologists to 
ensure that patients 
with suspicion of 
axSpA can be seen 
by a rheumatology 
specialist within 3 
weeks after referral.
The number of 
patients with 
a suspicion of 
axSpA that is 
assessed by a 
rheumatologist 
within 3 weeks 
after referral.
The number of 
patients with 
suspicion of axSpA 
referred to a 
rheumatologist.
7.2±2.5
second vote: 
86.7%.
69.6
QS3 Assessment Patients with 
suspicion of 
axSpA have 
their diagnostic 
work- up 
completed 
within 2 
months.
Timely diagnostic work- up by 
a rheumatologist is needed to 
ensure correct diagnosis and to 
achieve better long- term outcomes 
and improve their quality of life. 
Diagnostic work- up includes 
identification of SpA variables, 
laboratory and imaging results. 
Diagnostic work- up should be 
completed within 2 months after first 
appointment.
Evidence of local 
arrangements 
including sufficient 
number of 
rheumatologists and 
facilities and access 
to facilities in the 
given timeframe to 
ensure that patients 
with suspicion 
of axSpA have a 
diagnostic work- up 
within 2 months after 
first appointment by 
a rheumatologist.
The number of 
patients with 
a suspicion of 
axSpA, in whom 
a diagnostic 
work up was 
completed within 
2 months after 
first appointment.
The number of 
patients with 
suspicion of 
axSpA seen for the 
first time by the 
rheumatologist 
more than 2 
months ago.
8.5±2.0 89.6
ASAS, Assessment of SpondyloArthritis International Society; axSpA, axial spondyloarthritis; NRS, numerical rating scale.
exist within each country and between different countries, and 
the ASAS- QS may serve as a tool for assessing, delivering and 
demanding optimal care for patients with axSpA in any country. 
QS are intended to help organisations improve quality of care 
and to monitor service improvements by supporting comparison 
of current performance. All ASAS- QS are achievable in daily 
care in an optimised situation and intend to minimise varia-
tion in quality of care. It is emphasised that ASAS is well aware 
that all QS are ideal visions of an optimal care provision which 
may currently not be realistic in many countries. ASAS- QS are 
aspirational but they may guide a wide range of purposes both 
locally and nationally. For example, people using services, care- 
providers and the public can use the QS to identify components 
of a high- quality service that is achievable.
Assessing quality of care provided to patients with rheumatic 
diseases is challenging because various areas need to be improved 
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Table 2 Quality standards (QS) for axial spondyloarthritis, treatment
no domain Statement rationale
Quality measure, 
category structure
Quality 
measure, 
category 
process, 
numerator
Quality 
measure, 
category 
process, 
denominator
level of 
agreement, nrS 
0–10
Agreement 
(nrS ≥7 by 
75% of ASAS 
members)
QS4 Monitoring Disease activity 
of patients 
with aSpA is 
monitored 
under the 
supervision of a 
rheumatologist 
with validated 
composite 
scores at least 
every 6 months.
Assessment of disease activity is of 
importance because of the correlation 
between clinical disease activity 
and syndesmophyte formation and 
between disease activity, function 
and health- related quality of life. 
Monitoring of disease activity by 
a rheumatologist (which implies 
the rheumatology team including 
physicians, nurses, other health 
professionals) is required because of 
multifaceted and ambiguous clinical 
symptoms of disease activity such 
as pain and disability. Assessment 
of disease activity using ASDAS 
is recommended. Repeating the 
assessment at regular intervals will 
ensure that the treatment of patients 
with axSpA is adapted when they 
need it.
Evidence of local 
arrangements to 
ensure that patients 
with aSpA have an 
assessment with 
validated composite 
scores at least every 
6 months.
The number 
of patients 
diagnosed with 
axSpA more 
than 6 months 
ago in whom 
disease activity 
was monitored 
with validated 
composite 
scores at least 
every 6 months.
The number 
of patients 
diagnosed with 
axSpA more than 
6 months ago.
8.0±2.2 81.7
QS5 Disease control In patients 
with axSpA 
and active 
disease despite 
conventional 
therapy, 
treatment 
escalation with 
biological drugs 
is discussed.
Treatment escalation is important 
to achieving disease control, which 
ideally results in remission or a low 
disease activity state, and therefore 
lower disease impact on functioning 
and everyday living. Patients who 
have high disease activity despite 
conventional therapy should discuss 
the use of biological drugs with 
their rheumatologist, taking patient 
profile, cost and access to biologicals 
into account. The 2016 update of 
the ASAS- EULAR management 
recommendations for axSpA provides 
criteria for recommending use of 
biologicals in patients with axial 
disease and high disease activity. The 
choice of intervention should be a 
joint decision between patient and 
rheumatologist.
Evidence of local 
arrangements to 
ensure that patients 
with axSpA and 
active disease 
despite conventional 
therapy are offered 
biologicals according 
to the ASAS 
recommendations to 
improve the chance 
of remission or low 
disease activity in 
the future.
The number 
of patients 
with axSpA 
and active 
disease despite 
conventional 
therapy 
in whom 
treatment with 
biologicals has 
been discussed.
The number of 
patients with 
axSpA and active 
disease despite 
conventional 
therapy.
9.2±1.5 94.8
QS6 Treatment, 
non- pharma
Patients with 
axSpA are 
informed about 
the benefits of 
regular exercise.
Physical activity should be an integral 
part of standard care throughout the 
course of disease in patients with 
axSpA. It is important that patients 
with axSpA are given information 
about benefits of regular exercise 
to reduce pain and stiffness and 
improve cardiorespiratory fitness and 
by doing so, also reducing the risk for 
cardiovascular disease. Actively raising 
the usefulness of exercising regularly 
will support patients in improving 
functioning and maintaining quality 
of life.
Evidence of local 
arrangements to 
encourage patients 
with axSpA to 
exercise on a regular 
basis.
The number 
of patients 
diagnosed with 
axSpA who are 
informed about 
the benefits of 
regular exercise.
The number 
of patients 
diagnosed with 
axSpA.
9.5±0.9 98.3
ASAS, Assessment of SpondyloArthritis International Society; ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, axial spondyloarthritis; NRS, numerical rating scale.
worldwide. For example, the number of rheumatologists for a 
certain population, healthcare utilisation for groups of patients 
with rheumatological disorders and appropriate outcome 
measures are some of the many issues which are also relevant 
for patients with axSpA. Moreover, scientific evidence might be 
scarce for the identified key areas for quality improvement. This 
was the case for example, when phrasing the ASAS- QS topic 
‘referral’. Whereas the delay in diagnosis is clearly an important 
gap in daily care experienced by many patients with axSpA, the 
challenge faced by the ASAS- QS group was twofold: (1) systems 
of referral to specialists vary worldwide and (2) evidence for 
the optimal time period is lacking. However, the ASAS- QS 
group was convinced that given a specific timeframe instead of 
phrasing like ‘timely or immediately’ is needed to force substan-
tial decrease in diagnostic delay. Moreover, the concept of QS 
requires the QS to be measurable (quantifiable).15 Hence, the 
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intention of the referral QS (QS1) is to reach high quality of care 
and therefore, enhance the practice of referrals to rheumatolo-
gists in patients with ‘suspicion of axSpA’ taking into account 
that rheumatologists are the medical specialists primarily respon-
sible for diagnosing and treating patients with axSpA. There is 
ample evidence that recognition of axSpA can be optimised by 
an adequate preselection of patients to be referred to the rheu-
matologist based on combination of different parameters such as 
inflammatory back pain, HLA- B27 or sacroiliitis.17 An obvious 
consideration is whether the ASAS- QS could be applied to other 
rheumatic diseases since many of the concepts utilised in these 
QS are relevant to other rheumatic conditions. However, three 
arguments may be against operationalisation of ASAS- QS into 
a different context: (1) axSpA is still less recognised than other 
inflammatory rheumatic diseases, has less recognisable features 
and takes longer time to diagnose, (2) ASAS is a group of experts 
in the field of spondyloarthritis and each step of the method-
ology relates explicitly to patients with SpA, and (3) the ASAS- QS 
group might not be representative for other rheumatic diseases. 
ASAS group apprehend that utilisation of disease- specific QS in a 
wider context might reduce the impact of such QS. Therefore, we 
suggest that ASAS- QS cannot be extrapolated to other rheumatic 
diseases directly, but may form a template for other diseases. 
QS are different from recommendations or guidelines. Recom-
mendations imply evidence- based actions that should be done in 
order to optimally diagnose and treat the disease. Usually, every 
important aspect of the disease is covered. QS are measurable 
constructs relating to specific aspects of the disease where there 
is unwarranted performance variation at the community level. 
Moreover, quality standards are going beyond the intention 
of recommendations because they intend to measure improve-
ment in quality of care. Yazdany et al showed in a community- 
based cohort that following systemic lupus erythematosus (SLE) 
quality measures was significantly protective against increased 
disease damage (Brief Index of Lupus Damage adjusted OR 0.4, 
95% CI 0.4 to 0.7).18
Our experience in developing disease- specific QS within an 
international group of SpA experts showed that the endorsement 
of QS sets into national public health domains can be ambitious. 
After the approval of QS 1 (referral) and QS 2 (time to specialist) 
failed in the initial voting round by the ASAS community, inten-
sive discussion, explanation and evaluation followed, resulting in 
an approval of the initial wording of QS 1 and 2. We learnt from 
that experience that implementation strategies must be accom-
panied at national levels by education about the meaning of QS 
in order to specify the intention of the QS: optimise quality of 
care at a community level instead of describing current practice 
of daily care.
In fact, implementation is a crucial aspect in the process of 
using the ASAS- QS at a national level. When implementing 
QS at a national level, several components such as data source, 
target population and reporting period have to be defined 
nationally prior to analysing QS in an individual country.19 A 
separate project is usually necessary for a successful implementa-
tion. ASAS did not decide on specific implementation strategies 
but leave it up to the national ASAS members. A major strength 
of this ASAS initiative is the participation of SpA experts from 
all over the world including other health professionals (physio-
therapists), and patients with axSpA. Thus, we think that inclu-
sion of a variety of stakeholders adds to the representativeness of 
the ASAS- QS set. Another strength is the restriction to the most 
important areas in which variation in quality of care has been 
identified by the panel. Focusing on five key areas (referral, rheu-
matology assessment, treatment, education/self- management 
and comorbidities) increases the probability to induce a substan-
tial improvement in quality of care. A limitation of our work 
is that we were not able to test the feasibility of the ASAS- QS 
in clinical practice worldwide. This is an important issue since 
previous research in the field of QS operationalised as indicators 
for rheumatoid arthritis showed that less than 50% of informa-
tion was available for measuring quality indicators in registries.20
With the help of the ASAS- QS one can focus on which resources 
and processes are needed to deliver high quality of care at the 
community level, thereby reducing significant healthcare dispar-
ities among populations and across regions. As indicated earlier, 
NICE published recently a quality assessment tool for patients 
with axSpA which was developed in parallel to the ASAS- QS 
set.13 None of the ASAS members participated in NICE guid-
ance and no ideas were exchanged between both groups. Inter-
estingly, areas addressed are quite similar and topics covered in 
both sets are the domains of referral and assessment as well as 
the importance of exercise and education about the disease.
The ASAS- QS set is not intended to replace other methods 
to improve quality of care. Furthermore, other methods, such 
as medical education, effective use of information technolo-
gies, and the development of evidence- based guidelines and 
practice recommendations, should complement the implemen-
tation of the ASAS- QS set. The proposed ASAS- QS for axSpA 
do not provide a comprehensive service specification. They 
rather define priority areas for quality of care improvement. 
The ASAS- QS should now be implemented at a national level for 
local quality improvement.
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